{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:26:49Z","timestamp":1793957209190,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.msard.2026.107934","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:51:18Z","timestamp":1789800678000},"page":"107934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["One target, two evidence streams: Rituximab versus ocrelizumab in relapsing multiple sclerosis: A design-stratified systematic review, meta-analysis, and concordance assessment"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-2978","authenticated-orcid":false,"given":"Yehia","family":"Nabil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9111-320X","authenticated-orcid":false,"given":"Anas","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1075-1055","authenticated-orcid":false,"given":"Enas Kamal Abdalaziz","family":"Seyed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-0822","authenticated-orcid":false,"given":"Baraah abu","family":"alsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9313-2656","authenticated-orcid":false,"given":"Safya E.","family":"Esmaeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0692-6309","authenticated-orcid":false,"given":"Mostafa","family":"Meshref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107934_bib0021","first-page":"304","article-title":"Ocrelizumab and Rituximab in multiple sclerosis: a single-centre retrospective cohort","volume":"11","author":"Alnajashi","year":"2025","journal-title":"J. Contemp. Med. Sci."},{"key":"10.1016\/j.msard.2026.107934_bib0025","article-title":"Tolerability and safety of switching from Rituximab to Ocrelizumab: evaluating factors associated with infusion related reactions","volume":"8","author":"Alvarez","year":"2022","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107934_bib0017","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.msard.2026.107934_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102802","article-title":"Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis","volume":"49","author":"Capasso","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107934_bib0008","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.78033","article-title":"Comparative safety profiles of Ocrelizumab and Rituximab in multiple sclerosis treatment using real-world evidence","volume":"99","author":"Cerono","year":"2026","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107934_bib0019","first-page":"1","article-title":"Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada","author":"Chu","year":"2026","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107934_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106564","article-title":"Effectiveness of anti-CD20 therapies following natalizumab discontinuation: insights from a cohort study","volume":"101","author":"Cunha","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107934_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107934_bib0024","article-title":"A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis","volume":"6","author":"Evertsson","year":"2020","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107934_bib0009","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/ana.78286","article-title":"Comparable infection risk of ocrelizumab and rituximab in multiple sclerosis in a nationwide Swedish cohort study","volume":"100","author":"Frisell","year":"2026","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107934_bib0029","series-title":"OCREVUS (ocrelizumab) Injection, For Intravenous Use: US Prescribing Information","author":"Genentech","year":"2022"},{"key":"10.1016\/j.msard.2026.107934_bib0003","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107934_bib0002","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107934_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/cjn.2025.10520","article-title":"A retrospective evaluation of Ocrelizumab and Rituximab discontinuation in a real-world patient cohort","author":"Hunt","year":"2026","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107934_bib0013","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"key":"10.1016\/j.msard.2026.107934_bib0005","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s13760-025-02766-3","article-title":"Efficacy of ocrelizumab versus rituximab in patients with relapsing-remitting multiple sclerosis","volume":"125","author":"Mounir","year":"2025","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2026.107934_bib0028","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1177\/13524585231168043","article-title":"ECTRIMS\/EAN consensus on vaccination in people with multiple sclerosis: improving immunization strategies in the era of highly active immunotherapeutic drugs","volume":"29","author":"Otero-Romero","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107934_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.msard.2026.107934_bib0011","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2026.107934_bib0032","article-title":"Double-blind, parallel-group study to compare the pharmacokinetics, efficacy, pharmacodynamics, safety, and immunogenicity of CYB704 (Proposed Ocrelizumab Biosimilar) and Ocrevus\u00ae in participants with relapsing multiple sclerosis (RMS) [STRI","author":"Randomized","year":"2025","journal-title":"ClinicalTrials.gov"},{"key":"10.1016\/j.msard.2026.107934_bib0012","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA Statement for reporting literature Searches in Systematic Reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst. Rev."},{"key":"10.1016\/j.msard.2026.107934_bib0004","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"Rituximab vs Ocrelizumab in relapsing-remitting multiple sclerosis","volume":"80","author":"Roos","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107934_bib0031","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75745-y","article-title":"Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial","volume":"14","author":"Sahraian","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2026.107934_bib0006","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70625","article-title":"Comparative effectiveness and safety of Rituximab versus Ocrelizumab in relapsing-remitting multiple sclerosis: a Finnish population-based matched cohort study","volume":"33","author":"Savolainen","year":"2026","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107934_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106858","article-title":"Non-inferiority of Rituximab versus OCrelizumab in Multiple sclerosis (ROC-MS)\u2014An individual participant data meta-analysis","volume":"105","author":"Schoof","year":"2026","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107934_bib0018","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"GRADE: grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2026.107934_bib0016","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2026.107934_bib0015","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2026.107934_bib0026","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107934_bib0007","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2600993","article-title":"Rituximab versus Ocrelizumab in newly diagnosed relapsing multiple sclerosis","volume":"395","author":"Torkildsen","year":"2026","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107934_bib0027","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:39:49Z","timestamp":1793954389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826009697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"alternative-id":["S2211034826009697"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107934","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One target, two evidence streams: Rituximab versus ocrelizumab in relapsing multiple sclerosis: A design-stratified systematic review, meta-analysis, and concordance assessment","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107934"}}